Home Cart Sign in  
Chemical Structure| 1349796-36-6 Chemical Structure| 1349796-36-6

Structure of PI3K-IN-1
CAS No.: 1349796-36-6

Chemical Structure| 1349796-36-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL765 analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM, and also inhibits DNA-PK and mTOR.

Synonyms: XL147 analog 2; SAR245409; SAR245409-Analog

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PI3K-IN-1

CAS No. :1349796-36-6
Formula : C31H29N5O6S
M.W : 599.66
SMILES Code : O=C(NC1=CC=C(S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=CC(OC)=CC(OC)=C4)=O)C=C1)C5=CC=C(C)C(OC)=C5
Synonyms :
XL147 analog 2; SAR245409; SAR245409-Analog
MDL No. :MFCD18252649
InChI Key :HJSSPYJVWLTYHG-UHFFFAOYSA-N
Pubchem ID :49867926

Safety of PI3K-IN-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PI3K-IN-1

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:9 nM

  • p110β

    PI3Kβ, IC50:113 nM

  • p110α

    PI3Kα, IC50:39 nM

  • p110δ

    PI3Kδ, IC50:43 nM

  • mTOR

    mTOR, IC50:157 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
GBM 6 7.5 µM 72 hours XL765 resulted in concentration-dependent decreases in cell viability PMC3064692
ST88-14 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with IC50 of 2.49 μM PMC3416967
MPNST642 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with IC50 of 1.93 μM PMC3416967
GBM 12 3.7 µM 72 hours XL765 resulted in concentration-dependent decreases in cell viability PMC3064692
GBM 8 5.7 µM 72 hours XL765 resulted in concentration-dependent decreases in cell viability PMC3064692
STS26T 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with IC50 of 1.75 μM PMC3416967
GBM 39 5.0 µM 72 hours XL765 resulted in concentration-dependent decreases in cell viability PMC3064692
GBM GS-2 7.7 µM 72 hours XL765 resulted in concentration-dependent decreases in cell viability PMC3064692
Rat nucleus pulposus-derived mesenchymal stem cells 25 μM 2 hours Inhibited the PI3K/Akt pathway, weakening the protective effect of melatonin against H2O2-induced oxidative stress injury PMC10711395
U87IDHmut cells 12 μM 24 hours To assess the effect of XL765 on cell proliferation, resulting in a 61.0 ± 10.6% reduction in cell number PMC6642106
SUM149 and MDA-MB-231 0.5 µM 6 hours Evaluate the inhibitory effect of XL765 combined with AS703026 on TNBC cell migration and invasion ability. Results showed that the combination significantly inhibited cell migration and invasion (p <0.001). PMC4643087
NHAIDHmut cells 32 μM 72 hours To assess the effect of XL765 on cell proliferation, resulting in a 55.7 ± 16% reduction in cell number PMC6642106
MDA-MB-231 40 nM 72 hours Evaluate the synergistic inhibitory effect of XL765 combined with AS703026 on TNBC cell proliferation. Results showed that the combination significantly inhibited cell proliferation (P < 0.001). PMC4643087
MPNST724 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with IC50 of 0.86 μM PMC3416967
S462 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with IC50 of 0.81 μM PMC3416967

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic nu/nu mice U87IDHmut orthotopic tumor model Oral 30 mg/kg Twice daily until the end of the experiment To evaluate the effect of XL765 on tumor growth and animal survival, showing that XL765 significantly prolonged animal survival but did not significantly affect tumor volume PMC6642106
Nude mice GS-2 and U87-MG glioblastoma models Oral 30mg/kg voxtalisib twice daily, 5mg/kg TMZ daily Daily administration until tumor was no longer detectable or animals had to be sacrificed To evaluate the effects of XL765 alone or in combination with TMZ on glioblastoma models, showing a significantly lower lactate-to-pyruvate ratio in treated groups, which was associated with enhanced animal survival. PMC4873419
SCID mice MPNST724 and STS26T xenograft models Oral 30mg/kg/bid Twice daily, continuous treatment XL765 significantly inhibited local and metastatic growth of MPNST xenografts PMC3416967
Mice Aldehyde dehydrogenase 5a1-deficient mouse model Intraperitoneal injection 5 mg/kg/day Once daily, up to 50 days XL-765 significantly extended the lifespan of aldh5a1?/? mice and induced weight gain PMC5114712
Nude mice Intracranial xenograft GBM 39 model Oral gavage 50 mg/kg Twice daily (6 hours apart) on days 21–25, 28–32, 49–53, and 56–60 XL765 shows activity as monotherapy and in combination with conventional therapeutics in a range of genetically diverse GBM xenografts. In vivo, XL765 administered by oral gavage resulted in greater than 12-fold reduction in median tumor bioluminescence compared with control (Mann–Whitney test p=0.001) and improvement in median survival (logrank p=0.05). TMZ alone showed a 30-fold decrease in median bioluminescence, but the combination XL765 + TMZ yielded a 140-fold reduction in median bioluminescence (Mann-Whitney test p=0.05) with a trend toward improvement in median survival (logrank p=0.09) compared with TMZ alone. PMC3064692

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.34mL

1.67mL

0.83mL

16.68mL

3.34mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories